Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage.
Introduction
Osteoporosis is a very common disease in postmenopausal women that manifests itself as fractures, most commonly at the spine, hip or wrist, and causes significant pain, morbidity and mortality [1] . Although osteoporosis is less prevalent in men, it has been estimated that 30% of all hip fractures occur in males and that one in eight men older than 50 years will experience an osteoporotic fracture [2] . Moreover, studies have shown that the mortality rate after fracture in men is higher compared with that in women [3, 4] . The interest in male osteoporosis has increased worldwide over recent years. Today osteoporosis in men is recognised as an important public health problem and has developed into a very active research issue.
Furthermore, the reported prevalence is increasing due to the increasing life expectancy of men, to the more frequent measurement of bone mineral density (BMD) in men with back pain and, probably, due to general changes in nutrition and lifestyle with consequent negative effects on calcium metabolism and the skeleton [5] . In our out-patient department, at this time, already 20% of the patients presenting for diagnosis and treatment of osteoporosis are men. Nevertheless the disease remains largely under-diagnosed and under-treated [6, 7] .
Aetiology of male osteoporosis
The causes of male osteoporosis are much more heterogeneous than in women, with 50-60% of men with osteoporosis being diagnosed as secondary cases, i.e. the disease is associated with one or more relevant medical conditions, medications or lifestyle factors that may result in bone loss and reduced bone strength [5, 8, 9] . In our own study of 500 males, we found that 52% had primary-idiopathic and 48% had secondary osteoporosis [5, 10] . Among the latter, we identified one subgroup of mono-aetiological (n = 124) and another of poly-aetiological (n = 116) origin. Table 1 shows the frequency of risk factors in these 240 males in terms of mono-and poly-aetiological subgroups. It is obvious that some are 'strong' pathogenetic risk factors, leading by themselves to secondary osteoporosis (e.g. factors 1, 4, 5, 11, 21) while other 'weak' risk factors only cause osteoporosis when in combination (e.g. factors 2, 3, 6-8 and 10). In an important fraction of osteoporotic men, hypercalcuria can be detected as an underlying disorder [11] . In our study we found this risk factor in 34 patients (Table 1) . Interestingly idiopathic hypercalcuria is an uncommon risk factor in osteoporotic women.
Epidemiology of fractures
The incidence of fractures is bimodal in both sexes, with peaks of fracture incidence in ado- lescence and young adulthood, lower rates in middle age and dramatic increases thereafter. From Fig. 1 it is obvious that men have a higher 'juvenile peak,' possibly due to a higher risk of traumatic impacts. The sharp increase in later life in men is as dramatic as in women but occurs 5-10 years later [12] . In younger men long bone fractures are more common, whereas vertebral and hip fractures predominate in the elderly, where skeletal fragility and falls are the major factors. The age adjusted incidence of hip fractures in men is one third to one half that of women. There is less information concerning vertebral fracture rates in men. According to data from the European Prospective Osteoporosis Study (EPOS) the age adjusted incidence in men seems to be rather high, reaching 50% of that in women [13] .
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Prevention of osteoporosis and fractures in men
Measures to avoid osteoporosis and associated fractures in men are similar to those in women. In early life, nutrition, regular exercise and lifestyle should aim to achieve a high peak bone mass. Calcium and vitamin D intake probably provide beneficial effects on bone mass and fractures, as in women. Reducing modifiable individual risk factors of diet and lifestyle, including alcohol and nicotine intake, remain important throughout life. For men suffering from one or more diseases or medical conditions with a high risk for the development of secondary osteoporosis (see Table 1 ), early detection and counteraction measures are important, e.g. reduction of glucocorticoid dosage if possible, androgen therapy in cases of hypogonadism, thiazides for idiopathic hypercalcuria and early surgical treatment of primary hyperparathyroidism [5, 14] .
In the elderly who are at risk for falls (e.g. those with reduced muscle strength, poor balance, previous falls) attempts to increase strength and balance or the use of a hip protector may be beneficial. Table 2 summarises general recommendations for the prevention of osteoporotic fractures in men.
Therapeutic dilemma in male osteoporosis
There is still a therapeutic dilemma in male osteoporosis. In comparison to postmenopausal osteoporosis only a very few approved therapies are available for osteoporosis in men. This is due to the fact that data from earlier trials on mixed female-male populations are not accepted and only a few of the requested randomised controlled studies on purely male cohorts have been performed.
Older drugs were approved for osteoporosis in general without the need for separate trials in men (e.g. calcium, fluoride, calcitonin, alfacalcidol) and, therefore, these are still available for treating men in some countries. During recent years, however, health authorities have Practicing medicine Table 1 ) and consider specific prophylactic measures Avoidance of falls and selective use of hip protection in elderly men approved every new substance only for postmenopausal osteoporosis, arguing that the respective phase-III trials had only been performed on this population. Furthermore, it was suggested that significant differences in bone biology might exist between the sexes, with the consequence of clinically relevant differences in therapeutic response. This procedure started with the bisphosphonates. As a consequence, today, the indication that a new drug can also be used for men follows after a delay of several years, or never follows if the pharmaceutical company involved estimates that a new independent study in men will be too expensive in relation to the potential increase in sales. The limited time of their patent protection may be another argument for giving up the idea of a study in men. This is a severe therapeutic disadvantage for men with osteoporosis. Prescribing innovative drugs to men with established osteoporosis 'off-label' is often difficult because insurance companies tend to be reluctant to reimburse the costs in many countries. Interestingly, so far, for all drugs that have also been studied in men, similar therapeutic results, in terms of BMD and fracture reducing potency, have been reported in men and women, disproving the argument of significant differences in bone biology of the female and male skeleton.
Therapy for osteoporosis in men
Aetiological therapy in secondary osteoporosis
Since about 50% of men are diagnosed with secondary osteoporosis, an aetiology-adapted treatment is more important in male than in postmenopausal osteoporosis. In hypogonadal men with secondary osteoporosis, androgen replacement therapy is effective [15] [16] [17] . We recommend combining this with calcium and vitamin D supplementation. We have found that subcutaneous or transdermal testosterone therapy, especially in advanced osteoporosis, is, per se, not sufficient to significantly improve BMD. Combining it with another bone turnover modifying substance is very often mandatory. Contraindications for androgen (lipid profile, prostatic cancer risk) have to be taken into consideration.
Other examples of therapies that may cause osteoporosis have been mentioned above, see 'Prevention'. In glucocorticoid-induced osteoporosis of rheumatic disease, too great a reduction in corticoids may increase the risk of osteoporosis, since an insufficient immunosuppressive effect will allow further degradation of bone tissue by proinflammatory cytokines [18] . Furthermore, insufficient disease control is associated with less mobility. For a number of mono-aetiolgical, and for the majority of polyaetiological, secondary osteoporoses (cf. Table 2 ) no aetiological therapies are available, i.e. the therapeutic strategy is no different from that used in idiopathic osteoporosis.
Treatment of idiopathic osteoporosis
In men with secondary osteoporosis, with no options for aetiology-related treatment, and in all cases of primary or idiopathic osteoporosis, an individually adapted therapeutic strategy has to be planned. A prerequisite for devising this long-term strategy is information on the history and present situation of the patient (Table 3) . Since osteoporosis is a chronic dis- Table 3 Patient's history and diagnostic data for devising an optimal, individually-adapted treatment strategy for men with osteoporosis
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1.
Anthropometric data: age, weight, height, BMI, loss of height since age 20 2.
Classification: primary, secondary (mono-or poly-aetiological) osteoporosis 3.
Clinical stage: severity of disease (BMD, fractures, pain) 4.
Risk factors: e.g. nutrition, mobility, muscle function, falls, sun exposure, conditions for secondary osteoporosis 5.
Disease activity: acute phase (severe back pain, recent fracture); chronic phase (moderate pain, fractures occurred years ago); bone turnover by biochemical markers (not obligatory) 6.
Previous treatments: general measures, pain therapy, specific bone turnover modifying therapies, duration, adverse events 7.
Expected compliance: age, mental health, comprehension of complex dosing and drug administration, previous acceptance, compliance and persistence with treatments BMI, body mass index; BMD, bone mineral density.
ease that has to be treated over several years, it is important to inform the patient carefully about the type of osteoporosis, severity, modifiable risk factors, future fracture risk, chances of improving pain, therapeutic mechanism of the selected medications and their possible side effects. Only then can good compliance and adherence be expected. Fig. 2 gives an overview of the choice of options for an individually tailored treatment regimen in men with idiopathic osteoporosis. With the exception of oestrogen and raloxifen, the same specific drugs as those used with women can be adopted in men. As mentioned above, however, not all are approved for this application in men. From the drugs listed in Fig. 2 , calcitonin, alfacalcidol and fluoride are older substances that do not exclude male osteoporosis. In most guidelines they are listed as second-line treatments. Bisphosphonates, strontium ranelate and teriparatide are firstline treatments, but only alendronate and, recently, risedronate have been approved for men. Teriparatide is approved for men in the US and Switzerland but not in the European Union countries. That means teriparatide and strontium ranelate can only be used off-label with careful documentation of the arguments for using these substances.
Calcitonin and fluoride
There are only older case reports or small studies on these two treatments in men with osteoporosis. There is one double blind, placebo-controlled study with the physiological osteoclast inhibitor calcitonin. In this study from Greece, 28 men with osteoporosis received either 200 IU of salmon calcitonin nasal spray plus 500 mg calcium per day or a placebo nasal spray plus calcium [19] . The authors described a significant lumbar spine BMD increase of 7.1% in the calcitonin group vs. 2.4% in the controls, in parallel with a higher decrease in bone resorption markers.
In our own prospective controlled, 3-year trial of 60 men with primary osteoporosis, we found a significantly lower vertebral fracture rate with low-dose-intermittent fluoride therapy compared to controls receiving only calcium plus vitamin D [20] . Further studies with fluoride in men have not been published, mainly due to the low cost of the substance and the fact that patent protection is lacking.
Bisphosphonates
In an uncontrolled study of 42 men (mean age 60.5 years) with established primary osteoporosis, the typical cyclical intermittent therapeutic regimen with etidronate resulted in an average annual increase of lumbar spine BMD of 3.2% and no significant change at the femoral neck [21] . There is no fracture data relating to the use of etidronate in males [22] .
Alendronate was shown to be effective for the treatment of male osteoporosis and was the first bisphosphonate to be approved for this indication [23] . The positive evidence was mainly based on two larger trials [24, 25] . The first trial was a 2 year multicentre, randomized, placebo-controlled US study on 241 men with primary osteoporosis or secondary due to hypogonadism [24] . In the second trial, an open prospective controlled study from our group, 134 men with idiopathic osteoporosis were treated over 3 years [25] . Both studies proved that the therapeutic results on BMD and fracture incidence with 10 mg alendronate daily were highly consistent with the effects known from postmenopausal osteoporosis. A study using alendronate 70 mg once weekly showed similar effects on BMD and bone turnover markers [26] . Nevertheless, the once weekly application was never approved in most countries.
Risedronate is a potent bisphosphonate that has been demonstrated to reduce both clinical vertebral and non-vertebral fractures in postmenopausal women within 6 months of treatment [27, 28] and to reduce hip fractures over a 3 year treatment period [29] . In men, risedronate has been shown to reduce vertebral fractures in patients with glucocorticoid-induced osteoporosis within 1 year [30] . The aim of our study was to investigate the therapeutic efficacy of risedronate in a purely male population with primary and secondary osteoporosis [31] . Eligible patients from our out-patient department were randomised to risedronate or control groups, stratified by the presence of prevalent vertebral fractures at baseline. All patients in the risedronate treatment arm received risedronate (5 mg daily), elementary calcium (1000 mg daily) and vitamin D (800 IU daily). Patients in the control group received one of two treatments depending on the presence of prevalent vertebral fractures: patients with prevalent vertebral fractures received alfacalcidol (1 mg daily) and calcium (500 mg daily); patients with no previous vertebral fractures received plain vitamin D (1000 IU daily) and calcium (800 mg daily). Patient visits were performed at baseline and 12 months. From the 316 men included in the study (risedronate, n = 158; controls, n = 158), a total of 84 (53.2%) and 81 (51.3%) patients in the risedronate and control groups, respectively, had at least one prevalent fracture. The baseline characteristics were similar and are summarised in Table 4 . In the risedronate group, 94 patients had primary osteoporosis and 64 patients had secondary osteoporosis. In the control group, the corresponding numbers were 92 and 66 patients. All 316 patients were re-examined at month 12.
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The findings of the primary efficacy endpoint showed that treatment with risedronate resulted in a significant increase in lumbar spine BMD compared with the control group. At 1 year, there was an average 4.7% increase in the lumbar spine BMD in patients treated with risedronate compared with an increase of 1.0% in the control group (p < 0.0001). Similarly, at the other BMD measurement sites -total hip and femoral neck -risedronate treatment produced a significant increase in BMD compared with the control group (Fig. 3) . Over 1 year the incidence of new vertebral fractures in the risedronate group was reduced by 60% versus the control group (p = 0.028: Fig. 4) significant effect on vertebral fractures we documented a significantly smaller decrease in height and steeper decrease in back pain in the risedronate treated patients [31] . Risedronate 35 mg per week was studied in an international, randomised, placebo-controlled study, where 192 patients received once weekly risedronate and 93 received placebo. All patients had an additional supplementation of 1000 mg calcium and 400-500 IU vitamin D [32] . After 2 years there was a significant increase in lumbar spine BMD of 5.8% in the risedronate group versus 1.2% in controls. In parallel with this, significant reductions in different markers of bone turnover could be proven for the active treatment arm. Regarding all new fracture events documented as adverse events, there was a positive trend in favour of risedronate but no significant difference (7.7% placebo, 4.9% risedronate).
Risedronate 35 mg once weekly has been approved recently as a second bisphosphonate for the treatment of men with a high fracture risk. There are, so far, no relevant studies on pamidronate, ibandronate and zoledronate in male osteoporosis.
Teriparatide and strontium ranelate
Two trials have studied the osteoanabolic effect of parathyroid hormone (PTH) in men with osteoporosis. The first was a small pilot study (n = 23) with daily injections of 400 IU PTH (1-34) (Teriparatide) in 10 patients and placebo injections in 13 [33] . After 18 months, the average lumbar spine BMD had increased by 13.5% in the PTH group and was unchanged in placebo group (p < 0.001). This mean rate of gain in BMD was consistent with the rate seen in a pivotal fracture trial in postmenopausal osteoporosis [34] . A larger international trial of 437 men with osteoporosis (daily dose of 20 mg or 40 mg rhPTH or placebo, subcutaneously) over 11 months plus 18 months follow-up found similar effects on BMD and a significantly lower rate of vertebral fractures for the pooled PTH groups [35, 36] .
The therapeutic results with strontium ranelate in postmenopausal osteoporosis are very convincing [37] , but so far no data on male osteoporosis have been published. First results of an ongoing head-to-head trial with alendronate and strontium ranelate show, at the very least, that the latter is not inferior.
